zontivity Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Zontivity, and when can generic versions of Zontivity launch?
Zontivity is a drug marketed by Key Therap and is included in one NDA. There are two patents protecting this drug.
This drug has one hundred and sixty-four patent family members in thirty-seven countries.
The generic ingredient in ZONTIVITY is vorapaxar sulfate. Additional details are available on the vorapaxar sulfate profile page.
DrugPatentWatch® Generic Entry Outlook for Zontivity
Zontivity was eligible for patent challenges on May 8, 2018.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 23, 2027. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for zontivity?
- What are the global sales for zontivity?
- What is Average Wholesale Price for zontivity?
Summary for zontivity
| International Patents: | 164 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 47 |
| Clinical Trials: | 5 |
| Patent Applications: | 6 |
| Drug Prices: | Drug price information for zontivity |
| What excipients (inactive ingredients) are in zontivity? | zontivity excipients list |
| DailyMed Link: | zontivity at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for zontivity
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for zontivity
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Vanderbilt University Medical Center | Phase 4 |
| Vanderbilt University | Phase 4 |
| University of Florida | Phase 4 |
US Patents and Regulatory Information for zontivity
zontivity is protected by two US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of zontivity is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting zontivity
Thrombin receptor antagonists
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS
Thrombin receptor antagonists
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION (MI) OR WITH PERIPHERAL ARTERIAL DISEASE (PAD)
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Key Therap | ZONTIVITY | vorapaxar sulfate | TABLET;ORAL | 204886-001 | May 8, 2014 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Key Therap | ZONTIVITY | vorapaxar sulfate | TABLET;ORAL | 204886-001 | May 8, 2014 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for zontivity
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Key Therap | ZONTIVITY | vorapaxar sulfate | TABLET;ORAL | 204886-001 | May 8, 2014 | ⤷ Sign Up | ⤷ Sign Up |
| Key Therap | ZONTIVITY | vorapaxar sulfate | TABLET;ORAL | 204886-001 | May 8, 2014 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for zontivity
See the table below for patents covering zontivity around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Hong Kong | 1070887 | Tricyclic thrombin receptor antagonists | ⤷ Sign Up |
| South Korea | 101039973 | ⤷ Sign Up | |
| Australia | 6690001 | Thrombin receptor antagonists | ⤷ Sign Up |
| Japan | 2007517804 | ⤷ Sign Up | |
| New Zealand | 548156 | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 0196330 | ⤷ Sign Up | |
| China | 1659162 | Tricyclic thrombin receptor antagonists | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for zontivity
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1495018 | 2015C/037 | Belgium | ⤷ Sign Up | PRODUCT NAME: VORAPAXAR, OU SON SEL OU SOLVAT PHARMACOLOGIQUEMENT ADMISSIBLE; AUTHORISATION NUMBER AND DATE: EU/1/14/976/001 |
| 1495018 | SPC/GB15/039 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: VORAPAXAR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF; REGISTERED: UK EU/1/14/976/001 20150121; UK EU/1/14/976/002 20150121; UK EU/1/14/976/003 20150121; UK EU/1/14/976/004 20150121; UK EU/1/14/976/005 20150121; UK EU/1/14/976/006 20150121 |
| 1495018 | CA 2015 00037 | Denmark | ⤷ Sign Up | PRODUCT NAME: VORAPAXAR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING VORAPAXARSULPHATE; REG. NO/DATE: EU/1/14/976/001-06 20150119 |
| 1495018 | 218 50011-2015 | Slovakia | ⤷ Sign Up | PRODUCT NAME: VORAPAXARIUMSULFAT; REGISTRATION NO/DATE: EU/1/14/976/001 - EU/1/14/976/006 20150121 |
| 1495018 | PA2015027 | Lithuania | ⤷ Sign Up | PRODUCT NAME: VORAPAXARUM; REGISTRATION NO/DATE: EU/1/14/976/001 - EU/1/14/976/006 20150119 |
| 1495018 | 1590037-6 | Sweden | ⤷ Sign Up | PRODUCT NAME: VORAPAXAR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF; REG. NO/DATE: EU/1/14/976/001 20150121 |
| 1495018 | 15C0047 | France | ⤷ Sign Up | PRODUCT NAME: VORAPAXAR,OU L'UN DE SES SELS OU SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/14/976/001-006 20150121 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
